Antiangiogenic effects of flavonoids and chalcones

Pharmacological Research

Volumn 57, Issue 4, 2008, Pages 259-265

  Mojzis, J ^a   Varinska, L ^a   Mojzisova, G ^a   Kostova, I ^b   Mirossay, L ^a  

^a P J AFÁRIK UNIVERSITY   (Slovakia)

^b MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

Author keywords

Chalcones; Flavonoids; Tumour angiogenesis

Indexed keywords

2 CHLORO 2',5' DIHYDROXYCHALCONE; 2' HYDROXY 4' METHOXYCHALCONE; 2',4' DIHYDROXY 6' METHOXY 3',5' DIMETHYLCHALCONE; ANTHOCYANIN; APIGENIN; CHALCONE DERIVATIVE; CHRYSIN; CYANIDIN; DELPHINIDIN; EPICATECHIN; EPIGALLOCATECHIN; EPIGALLOCATECHIN GALLATE; FISETIN; FLAVONOID; GENISTEIN; ISOXANTHOHUMOL; KAEMPFEROL; LICOCHALCONE E; LUTEOLIN; MALVIDIN CHLORIDE; MATRIX METALLOPROTEINASE; PELARGONIDIN; PEONIDIN; PETUNIDIN CHLORIDE; POLYPHENOL; QUERCETIN; SILIBININ; UNINDEXED DRUG; WOGONIN; XANTHOHUMOL;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; BREAST TUMOR; CANCER INHIBITION; DRUG ISOLATION; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; HUMAN; LUNG TUMOR; METASTASIS; MOLECULAR DYNAMICS; NONHUMAN; PHYTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RED WINE; REVIEW; TEA; TUMOR; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CHALCONES; FLAVONOIDS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 43049127754     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2008.02.005     Document Type: Review

References (107)

1. Coultas L., Chawengsaksophak K., and Rossant J. Endothelial cells and VEGF in vascular development. Nature 438 (2005) 937-945
2. Carmeliet P. Angiogenesis in health and disease. Nat Med 9 (2003) 653-660
3. Klagsbrun M., and Moses M.A. Molecular angiogenesis. Chem Biol 6 (1999) 217-224
4. Pepper M.S. Role of matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol 21 (2001) 1104-1117
5. Pages G., Milanini J., Richard D.E., Berra E., Gothie E., Vinals F., and Pouyssegur J. Signalling angiogenesis via p42/p44 MAP kinase cascade. Ann NY Acad Sci 902 (2000) 187-200
6. Vassalli J.-D., Sappino A.P., and Belin D. The plasminogen activator/plasmin system. J Clin Invest 88 (1991) 1067-1072
7. Basbaum C.B., and Werb Z. Focalized proteolysis: spatial and temporal regulation of extracellular matrix degradation at the cell surface. Curr Opin Cell Biol 8 (1996) 731-738
8. Murphy G., and Docherty A.J.P. The matrix metalloproteinases and their inhibitors. Am J Resp Cell Mol Biol 7 (1992) 120-125
9. Hiraoka N., Allen E., Apel I.J., Gyetko M.R., and Weiss S.J. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell 95 (1998) 365-377
10. Nagase H. Activation mechanism of matrix metalloproteinases. Biol Chem 378 (1997) 151-160
11. Brew K., Dinakarpandian D., and Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochem Biophys Acta 1477 (2000) 267-283
12. Pasterkamp G., Schoneveld A.D., Hijnen D.J., de Kleijn D.P., Teepen H., van der Wal A.C., and Borst C. Atherosclerotic arterial remodelling and the localization of macrophages and matrix metalloproteinases 1, 2 and 9 in the human coronary artery. Atherosclerosis 150 (2000) 245-253
13. Visse R., and Nagase H. Matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases: structure, function, and biochemistry. Circ Res 92 (2003) 827-839
14. Bouïs D., Kusumanto Y., Meijer C., Mulder N.H., and Hospers G.A.P. A review on pro- and anti-angiogenic factors as targets of clinical intervention. Pharmacol Res 53 (2006) 89-103
15. Bergers G., and Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3 (2003) 401-410
16. Folkman J. Tumour angiogenesis: therapeutic implications. N Engl J Med 285 (1971) 1182-1186
17. Hida K., and Klagsbrun M. A new perspective on tumor endothelial cells: unexpected chromosome and centrosome abnormalities. Cancer Res 65 (2005) 2507-2510
18. Hendrix M.J., Seftor E.A., Hess A.R., and Seftor R.E. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer 3 (2003) 411-421
19. van der Schaft D.W., Seftor R.E., Seftor E.A., Hess A.R., Gruman L.M., Kirschmann D.A., Yokoyama Y., Griffioen A.W., and Hendrix M.J. Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells. J Natl Cancer Inst 96 (2004) 1473-1477
20. Brem H., Gresser I., Grosfeld J., and Folkman J. The combination of antiangiogenic agents to inhibit primary tumour growth and metastasis. J Pediatr Surg 28 (1993) 1253-1257
21. Beecken W.D., Fernandez A., Panigrahy D., Achilles E.G., Kisker O., Flynn E., Joussen A.M., Folkman J., and Shing Y. Efficacy of antiangiogenic therapy with TNP-470 in superficial and invasive bladder cancer models in mice. Urology 56 (2000) 521-526
22. Cox M.C., Dahut W.L., and Figg W.D. The use of thalidomide in androgen-independent prostate cancer. Urol Oncol 24 (2006) 246-249
23. Kulke M.H., Stuart K., Enzinger P.C., Ryan D.P., Clark J.W., Muzikansky A., Vincitore M., Michelini A., and Fuchs C.S. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumours. J Clin Oncol 24 (2006) 401-406
24. Shih T., and Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 28 (2006) 1779-1802
25. Smith J.K., Mamoon N.M., and Duhe R.J. Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapy. Oncol Res 14 (2004) 175-225
26. Lee K.W., and Lee H.J. The roles of polyphenols in cancer chemoprevention. Biofactors 26 (2006) 105-121
27. Harborne J.B., and Williams C. Advances in flavonoid research since 1992. Phytochemistry 55 (2000) 481-504
28. Moridani M.Y., Pourahmad J., Bui H., Siraki A., and O'Brien P.J. Dietary flavonoid iron complexes as cytoprotective superoxide radical scavengers. Free Radic Biol Med 34 (2003) 243-253
29. Iraz M., Erdogan H., Kotuk M., Yaǧmurca M., Ki{dotless}li{dotless}c T., Ermis H., Fadillioǧlu E., and Yildirim Z. Ginkgo biloba inhibits bleomycin-induced lung fibrosis in rats. Pharmacol Res 53 (2006) 310-316
30. Kim J.D., Liu L., Guo W., and Meydani M. Chemical structure of flavonols in relation to modulation of angiogenesis and immune-endothelial cell adhesion. J Nutr Biochem 17 (2006) 165-176
31. Moon H.K., Yang E.S., and Park J.W. Protection of peroxynitrite-induced DNA damage by dietary antioxidants. Arch Pharm Res 29 (2006) 213-217
32. Park H.H., Lee S., Oh J.M., Lee M.S., Yoon K.H., Park B.H., Kim J.W., Song H., and Kim S.H. Anti-inflammatory activity of fisetin in human mast cells (HMC-1). Pharmacol Res 55 (2007) 31-37
33. Mojžiš J., Hviščová K., Germanová D., Bukovičová D., and Mirossay L. Protective effect of quercetin on ischemia/reperfusion-induced gastric mucosal injury in rats. Physiol Res 50 (2001) 501-506
34. Mojžišová G., and Kuchta M. Dietary flavonoids and risk of coronary heart disease. Physiol Res 50 (2001) 529-535
35. Zern T.L., Wood R.J., Greene C., West K.L., Liu Y., Aggarwal D., Shachter N.S., and Fernandez M.L. Grape polyphenols exert a cardioprotective effect in pre- and postmenopausal women by lowering plasma lipids and reducing oxidative stress. J Nutr 135 (2005) 1911-1917
36. Ren W., Qiao Z., Wang H., Zhu L., and Zhang L. Flavonoids: promising anticancer agents. Med Res Rev 23 (2003) 519-534
37. Oak M.H., El Bedoui J., and Schini-Kerth V.B. Antiangiogenic properties of natural polyphenols from red wine and green tea. J Nutr Biochem 16 (2005) 1-8
38. Oak M.H., Chataigneau M., Keravis T., Chataigneau T., Beretz A., Andriantsitohaina R., Stoclet J.C., Chang S.J., and Schini-Kerth V.B. Red wine polyphenolic compounds inhibit vascular endothelial growth factor expression in vascular smooth muscle cells by preventing the activation of the p38 mitogen-activated protein kinase pathway. Arterioscler Thromb Vasc Biol 23 (2003) 1001-1007
39. Oak M.H., El Bedoui J., Anglard P., and Schini-Kerth V.B. Red wine polyphenolic compounds strongly inhibit pro-matrix metalloproteinase-2 expression and its activation in response to thrombin via direct inhibition of membrane type 1-matrix metalloproteinase in vascular smooth muscle cells. Circulation 110 (2004) 1861-1867
40. Oak M.H., Bedoui J.E., Madeira S.V., Chalupsky K., and Schini-Kerth V.B. Delphinidin and cyanidin inhibit PDGF(AB)-induced VEGF release in vascular smooth muscle cells by preventing activation of p38 MAPK and JNK. Br J Pharmacol 149 (2006) 283-290
41. Demeule M., Brossard M., Pagé M., Gingras D., and Béliveau R. Matrix metalloproteinase inhibition by green tea catechins. Biochim Biophys Acta 1478 (2000) 51-60
42. Annabi B., Lachambre M.P., Bousquet-Gagnon N., Page M., Gingras D., and Beliveau R. Green tea polyphenol (-)-epigallocatechin 3-gallate inhibits MMP-2 secretion and MT1-MMP-driven migration in glioblastoma cells. Biochim Biophys Acta 1542 (2002) 209-220
43. Sartippour M.R., Heber D., Zhang L., Beatty P., Elashoff D., Elashoff R., Go V.L., and Brooks M.N. Inhibition of fibroblast growth factors by green tea. Int J Oncol 21 (2002) 487-491
44. Sartippour M.R., Shao Z.M., Heber D., Beatty P., Zhang L., Liu C., Ellis L., Liu W., Go V.L., and Brooks M.N. Green tea inhibits vascular endothelial growth factor (VEGF) induction in human breast cancer cells. J Nutr 132 (2002) 2307-2311
45. Cao Y., and Cao R. Angiogenesis inhibited by drinking tea. Nature 398 (1999) 381
46. Jung Y.D., Kim M.S., Shin B.A., Chay K.O., Ahn B.W., Liu W., Bucana C.D., Gallick G.E., and Ellis L.M. EGCG a major component of green tea, inhibits tumour growth by inhibiting VEGF induction in human colon carcinoma cells. Br J Cancer 84 (2001) 844-850
47. Masuda M., Suzui M., Lim J.T., Deguchi A., Soh J.W., and Weinstein I.B. Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction. J Exp Ther Oncol 2 (2002) 350-359
48. Zhang Q., Tang X., Lu Q., Zhang Z., Rao J., and Le A.D. Green tea extract and (-)-epigallocatechin-3-gallate inhibit hypoxia- and serum-induced HIF-1α protein accumulation and VEGF expression in human cervical carcinoma and hepatoma cells. Mol Cancer Ther 5 (2006) 1227-1238
49. Beltz L.A., Bayer D.K., Moss A.L., and Simet I.M. Mechanisms of cancer prevention by green and black tea polyphenols. Anticancer Agents Med Chem 6 (2006) 389-406
50. Sagar S.M., Yance D., and Wong R.K. Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer-Part 2. Curr Oncol 13 (2006) 99-107
51. Adhami V.M., Ahmad N., and Mukhtar H. Molecular targets for green tea in prostate cancer prevention. J Nutr 133 (2003) 2417S-2424S
52. Mantena S.K., Meeran S.M., Elmets C.A., and Katiyar S.K. Orally administered green tea polyphenols prevent ultraviolet radiation-induced skin cancer in mice through activation of cytotoxic T cells and inhibition of angiogenesis in tumors. J Nutr 135 (2005) 2871-2877
53. Mantena S.K., Roy A.M., and Katiyar S.K. Epigallocatechin-3-gallate inhibits photocarcinogenesis through inhibition of angiogenic factors and activation of CD8+ T cells in tumors. Photochem Photobiol 81 (2005) 1174-1179
54. Lamy S., Blanchette M., Michaud-Levesque J., Lafleur R., Durocher Y., Moghrabi A., Barrette S., Gingras D., and Beliveau R. Delphinidin, a dietary anthocyanidin, inhibits vascular endothelial growth factor receptor-2 phosphorylation. Carcinogenesis 27 (2006) 989-996
55. Singh R.P., Dhanalakshmi S., Agarwal C., and Agarwal R. Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and down-regulation of survivin, Akt and NF-kappaB: implications for angioprevention and antiangiogenic therapy. Oncogene 24 (2005) 1188-1202
56. Singh R.P., Deep G., Chittezhath M., Kaur M., Dwyer-Nield L.D., Malkinson A.M., and Agarwal R. Effect of silibinin on the growth and progression of primary lung tumors in mice. J Natl Cancer Inst 98 (2006) 846-855
57. Jeong Y.M., Choi Y.G., Kim D.S., Park S.H., Yoon J.A., Kwon S.B., Park E.S., and Park K.C. Cytoprotective effect of green tea extract and quercetin against hydrogen peroxide-induced oxidative stress. Arch Pharm Res 28 (2005) 1251-1256
58. Mojžišová G., Mirossay L., Kučerová D., Kyselovič J., Miroššay A., and Mojžiš J. Protective effect of selected flavonoids on in vitro daunorubicin-induced cardiotoxicity. Phytother Res 20 (2006) 110-114
59. Wang L., Tu Y.C., Lian T.W., Hung J.T., Yen J.H., and Wu M.J. Distinctive antioxidant and antiinflammatory effects of flavonols. J Agric Food Chem 54 (2006) 9798-9804
60. Braganhol E., Zamin L.L., Canedo A.D., Horn F., Tamajusuku A.S., Wink M.R., Salbego C., and Battastini A.M. Antiproliferative effect of quercetin in the human U138MG glioma cell line. Anticancer Drugs 17 (2006) 663-671
61. Gulati N., Laudet B., Zohrabian V.M., Murali R., and Jhanwar-Uniyal M. The antiproliferative effect of quercetin in cancer cells is mediated via inhibition of the PI3K-Akt/PKB pathway. Anticancer Res 26 (2006) 1177-1181
62. Tan W.F., Lin L.P., Li M.H., Zhang Y.X., Tong Y.G., Xiao D., and Ding J. Quercetin, a dietary-derived flavonoid, possesses antiangiogenic potential. Eur J Pharmacol 459 (2003) 255-262
63. Igura K., Ohta T., Kuroda Y., and Kaji K. Resveratrol and quercetin inhibit angiogenesis in vitro. Cancer Lett 171 (2001) 11-16
64. Vijayababu M.R., Arunkumar A., Kanagaraj P., Venkataraman P., Krishnamoorthy G., and Arunakaran J. Quercetin downregulates matrix metalloproteinases 2 and 9 proteins expression in prostate cancer cells (PC-3). Mol Cell Biochem 287 (2006) 109-116
65. Jackson S.J., and Venema R.C. Quercetin inhibits eNOS, microtubule polymerization, and mitotic progression in bovine aortic endothelial cells. J Nutr 136 (2006) 1178-1184
66. Shim H.Y., Park J.H., Paik H.D., Nah S.Y., Kim D.S., and Han Y.S. Genistein-induced apoptosis of human breast cancer MCF-7 cells involves calpain-caspase and apoptosis signaling kinase 1-p38 mitogen-activated protein kinase activation cascades. Anticancer Drugs 18 (2007) 649-657
67. Ismail I.A., Kang K.S., Lee H.A., Kim J.W., and Sohn Y.K. Genistein-induced neuronal apoptosis and G2/M cell cycle arrest is associated with MDC1 up-regulation and PLK1 down-regulation. Eur J Pharmacol 575 (2007) 12-20
68. Choi E.J., Kim T., and Lee M.S. Pro-apoptotic effect and cytotoxicity of genistein and genistin in human ovarian cancer SK-OV-3 cells. Life Sci 80 (2007) 1403-1408
69. Guo Y., Wang S., Hoot D.R., and Clinton S.K. Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isoflavones. J Nutr Biochem 18 (2007) 408-417
70. Farina H.G., Pomies M., Alonso D.F., and Gomez D.E. Antitumor and antiangiogenic activity of soy isoflavone genistein in mouse models of melanoma and breast cancer. Oncol Rep 16 (2006) 885-891
71. Sasamura H., Takahashi A., Yuan J., Kitamura H., Masumori N., Miyao N., Itoh N., and Tsukamoto T. Antiproliferative and antiangiogenic activities of genistein in human renal cell carcinoma. Urology 64 (2004) 389-393
72. Gu Y., Zhu C.F., Iwamoto H., and Chen J.S. Genistein inhibits invasive potential of human hepatocellular carcinoma by altering cell cycle, apoptosis, and angiogenesis. World J Gastroenterol 11 (2005) 6512-6517
73. Su S.J., Yeh T.M., Chuang W.J., Ho C.L., Chang K.L., Cheng H.L., Liu H.S., Cheng H.L., Hsu P.Y., and Chow N.H. The novel targets for anti-angiogenesis of genistein on human cancer cells. Biochem Pharmacol 69 (2005) 307-318
74. Piao M., Mori D., Satoh T., Sugita Y., and Tokunaga O. Inhibition of endothelial cell proliferation, in vitro angiogenesis, and the down-regulation of cell adhesion-related genes by genistein. Combined with a cDNA microarray analysis. Endothelium 13 (2006) 249-266
75. Shukla S., and Gupta S. Apigenin-induced cell cycle arrest is mediated by modulation of MAPK, PI3K-Akt, and loss of cyclin D1 associated retinoblastoma dephosphorylation in human prostate cancer cells. Cell Cycle 6 (2007) 1102-1114
76. Mak P., Leung Y.K., Tang W.Y., Harwood C., and Ho S.M. Apigenin suppresses cancer cell growth through ERbeta. Neoplasia 8 (2006) 896-904
77. Ujiki M.B., Ding X.Z., Salabat M.R., Bentrem D.J., Golkar L., Milam B., Talamonti M.S., Bell Jr. R.H., Iwamura T., and Adrian T.E. Apigenin inhibits pancreatic cancer cell proliferation through G2/M cell cycle arrest. Mol Cancer 5 (2006) 1-8
78. Fang J., Zhou Q., Liu L.Z., Xia C., Hu X., Shi X., and Jiang B.H. Apigenin inhibits tumor angiogenesis through decreasing HIF-1alpha and VEGF expression. Carcinogenesis 28 (2007) 858-864
79. Liu L.Z., Fang J., Zhou Q., Hu X., Shi X., and Jiang B.H. Apigenin inhibits expression of vascular endothelial growth factor and angiogenesis in human lung cancer cells: implication of chemoprevention of lung cancer. Mol Pharmacol 68 (2005) 635-643
80. Fang J., Xia C., Cao Z., Zheng J.Z., Reed E., and Jiang B.H. Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB J 19 (2005) 342-353
81. Fu B., Xue J., Li Z., Shi X., Jiang B.H., and Fang J. Chrysin inhibits expression of hypoxia-inducible factor-1alpha through reducing hypoxia-inducible factor-1alpha stability and inhibiting its protein synthesis. Mol Cancer Ther 6 (2007) 220-226
82. Lin C.M., Chang H., Li S.Y., Wu I.H., and Chiu J.H. Chrysin inhibits lipopolysaccharide-induced angiogenesis via down-regulation of VEGF/VEGFR-2(KDR) and IL-6/IL-6R pathways. Planta Med 72 (2006) 708-714
83. Schindler R., and Mentlein R. Flavonoids and vitamin E reduce the release of the angiogenic peptide vascular endothelial growth factor from human tumor cells. J Nutr 136 (2006) 1477-1482
84. Kim M.R., Lee J.Y., Lee H.H., Aryal D.K., Kim Y.G., Kim S.K., Woo E.R., and Kang K.W. Antioxidative effects of quercetin-glycosides isolated from the flower buds of Tussilago farfara L. Food Chem Toxicol 44 (2006) 1299-1307
85. Sung B., Pandey M.K., Aggarwal B.B., Fisetin, an inhibitor of cyclin-dependent kinase 6, down-regulates nuclear factor-kappaB-regulated cell proliferation, and antiapoptotic and metastatic gene products through the suppression of TAK-1 and receptor-interacting protein-regulated IkappaBalpha kinase activation. Mol Pharmacol 71 (2007) 1703-1714
86. Joussen A.M., Rohrschneider K., Reichling J., Kirchhof B., and Kruse F.E. Treatment of corneal neovascularization with dietary isoflavonoids and flavonoids. Exp Eye Res 71 (2000) 483-487
87. Lin C.M., Chang H., Chen Y.H., Wu I.H., and Chiu J.H. Wogonin inhibits IL-6-induced angiogenesis via down-regulation of VEGF and VEGFR-1, not VEGFR-2. Planta Med 72 (2006) 1305-1310
88. Lin C.M., Chang H., Chen Y.H., Li S.Y., Wu I.H., and Chiu J.H. Protective role of wogonin against lipopolysaccharide-induced angiogenesis via VEGFR-2, not VEGFR-1. Int Immunopharmacol 6 (2006) 1690-1698
89. Bagli E., Stefaniotou M., Morbidelli L., Ziche M., Psillas K., Murphy C., and Fotsis T. Luteolin inhibits vascular endothelial growth factor-induced angiogenesis; inhibition of endothelial cell survival and proliferation by targeting phosphatidylinositol 3′-kinase activity. Cancer Res 64 (2004) 7936-7946
90. Hasebe Y., Egawa K., Yamazaki Y., Kunimoto S., Hirai Y., Ida Y., and Nose K. Specific inhibition of hypoxia-inducible factor (HIF)-1 alpha activation and of vascular endothelial growth factor (VEGF) production by flavonoids. Biol Pharm Bull 26 (2003) 1379-1383
91. Gazák R., Walterová D., and Kren V. Silybin and silymarin-new and emerging applications in medicine. Curr Med Chem 14 (2007) 315-338
92. Agarwal R., Agarwal C., Ichikawa H., Singh R.P., and Aggarwal B.B. Anticancer potential of silymarin: from bench to bed side. Anticancer Res 26 (2006) 4457-4498
93. Yang S.H., Lin J.K., Huang C.J., Chen W.S., Li S.Y., and Chiu J.H. Silibinin inhibits angiogenesis via Flt-1, but not KDR, receptor up-regulation. J Surg Res 128 (2005) 140-146
94. Tomas-Barberen F.A., and Clifford M.N. Flavanones, chalcones and dihydrochalcones: nature, occurrence and dietary burden. J Sci Food Agric 80 (2000) 1073-1080
95. Hsu Y.L., Kuo P.L., Chiang L.C., and Lin C.C. Isoliquiritigenin inhibits the proliferation and induces the apoptosis of human non-small cell lung cancer A549 cells. Clin Exp Pharmacol Physiol 31 (2004) 414-418
96. Liu X., and Go M.L. Antiproliferative properties of piperidinylchalcones. Bioorg Med Chem 14 (2006) 153-163
97. Modzelewska A., Pettit C., Achanta G., Davidson N.E., Huang P., and Khan S.R. Anticancer activities of novel chalcone and bis-chalcone derivatives. Bioorg Med Chem 14 (2006) 3491-3495
98. Nam N.H., Kim Y., You Y.J., Hong D.H., Kim H.M., and Ahn B.Z. Cytotoxic 2′,5′-dihydroxychalcones with unexpected antiangiogenic activity. Eur J Med Chem 38 (2003) 179-187
99. Bertl E., Becker H., Eicher T., Herhaus C., Kapadia G., Bartsch H., and Gerhauser C. Inhibition of endothelial cell functions by novel potential cancer chemopreventive agents. Biochem Biophys Res Commun 325 (2004) 287-295
100. Gerhauser C. Beer constituents as potential cancer chemopreventive agents. Eur J Cancer 41 (2005) 1941-1954
101. Albini A., Dell'Eva R., Vene R., Ferrari N., Buhler D.R., Noonan D.M., and Fassina G. Mechanisms of the antiangiogenic activity by the hop flavonoid xanthohumol: NF-kappaB and Akt as targets. FASEB J 20 (2006) 20527-20529
102. Dell'Eva R., Ambrosini C., Vannini N., Piaggio G., Albini A., and Ferrari N. AKT/NF-kappaB inhibitor xanthohumol targets cell growth and angiogenesis in hematologic malignancies. Cancer 110 (2007) 2007-2011
103. Chang H.J., Yoon G., Park J.S., Kim M.H., Baek M.K., Kim N.H., Shin B.A., Ahn B.W., Cheon S.H., and Jung Y.D. Induction of apoptosis by the licochalcone E in endothelial cells via modulation of NF-kappaB and Bcl-2 Family. Biol Pharm Bull 30 (2007) 2290-2293
104. Lee Y.S., Lim S.S., Shin K.H., Kim Y.S., Ohuchi K., and Jung S.H. Anti-angiogenic and anti-tumor activities of 2′-hydroxy-4′-methoxychalcone. Biol Pharm Bull 29 (2006) 1028-1031
105. Zhu X.F., Xie B.F., Zhou J.M., Feng G.K., Liu Z.C., Wei X.Y., Zhang F.X., Liu M.F., and Zeng Y.X. Blockade of vascular endothelial growth factor receptor signal pathway and antitumor activity of ON-III (2′,4′-dihydroxy-6′-methoxy-3′,5′-dimethyl chalcone), a component from Chinese herbal medicine. Mol Pharmacol 67 (2005) 1444-1450
106. Mojžišová G., Mojžiš J., Pilátová M., Vohárová V., Varinská L., Perjesi P., Sarišský M., and Mirossay L. Antiproliferative and antiangiogenic effects of selected chalcones. Acta Pharmacol Sin 27 (2006) 338
107. Mojžiš J., Varinská L., Perjesi P.G., and Mojžišová G. Antiangiogenic effect of newly synthesized chalcones. Eur J Cancer 5 (2007) 87